Elahere approval expands options for chemotherapy resistant ovarian cancer Elahere, a new treatment for ovarian cancer that no longer responds to chemotherapy, has received go ahead in England so it can be offered through the NHS. The reports describe Elahere as the first new drug for chemotherapy…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.